CLINICAL RESEARCH: HEART FAILURE
Coenzyme Q10An Independent Predictor of Mortality in Chronic Heart Failure
Sarah L. Molyneux, PhD*,
Christopher M. Florkowski, MD*,*,
Peter M. George, MB, BS*,
Anna P. Pilbrow, PhD ,
Christopher M. Frampton, PhD,
Michael Lever, PhD* and
A. Mark Richards, MD, PhD
* Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
The Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago (Christchurch), Christchurch, New Zealand
Manuscript received March 3, 2008;
revised manuscript received July 14, 2008,
accepted July 21, 2008.
* Reprint requests and correspondence: Dr. Christopher M. Florkowski, Clinical Biochemistry Unit, Canterbury Health Laboratories, P.O. Box 151, Christchurch 8140, New Zealand (Email: chris.florkowski{at}cdhb.govt.nz).
 |
Abstract
|
|---|
Objectives: The aim of this study was to investigate the relationship between plasma coenzyme Q10 (CoQ10) and survival in patients with chronic heart failure (CHF).
Background: Patients with CHF have low plasma concentrations of CoQ10, an essential cofactor for mitochondrial electron transport and myocardial energy supply. Additionally, low plasma total cholesterol (TC) concentrations have been associated with higher mortality in heart failure. Plasma CoQ10 is closely associated with low-density lipoprotein cholesterol (LDL-C), which might contribute to this association. Therefore we tested the hypothesis that plasma CoQ10 is a predictor of total mortality in CHF and could explain this association.
Methods: Plasma samples from 236 patients admitted to the hospital with CHF, with a median (range) duration of follow-up of 2.69 (0.12 to 5.75) years, were assayed for LDL-C, TC, and total CoQ10.
Results: Median age at admission was 77 years. Median (range) CoQ10 concentration was 0.68 (0.18 to 1.75) µmol/l. The optimal CoQ10 concentration for prediction of mortality (established with receiver-operator characteristic [ROC] curves) was 0.73 µmol/l. Multivariable analysis allowing for effects of standard predictors of survival—including age at admission, gender, previous myocardial infarction, N-terminal peptide of B-type natriuretic peptide, and estimated glomerular filtration rate (modification of diet in renal disease)—indicated CoQ10 was an independent predictor of survival, whether dichotomized at the ROC curve cut-point (hazard ratio [HR]: 2.0; 95% confidence interval [CI]: 1.2 to 3.3) or the median (HR: 1.6; 95% CI: 1.0 to 2.6).
Conclusions: Plasma CoQ10 concentration was an independent predictor of mortality in this cohort. The CoQ10 deficiency might be detrimental to the long-term prognosis of CHF, and there is a rationale for controlled intervention studies with CoQ10.
Key Words: chronic heart failure • coenzyme Q10 • mortality
|
Abbreviations and Acronyms
| | CHF = chronic heart failure | | CI = confidence interval | | CoQ10
= coenzyme Q10 | | GFR = glomerular filtration rate | | LDL-C = low-density lipoprotein cholesterol | | MDRD = modification of diet in renal disease | | MI = myocardial infarction | | NT-proBNP = N-terminal peptide of B-type natriuretic peptide | | NYHA = New York Heart Association | | ROC = receiver-operator characteristic | | TC = total cholesterol |
|
Coenzyme Q10 (CoQ10) is a fat-soluble quinone found in all cells, essential for adenosine triphosphate generation via mitochondrial oxidative phosphorylation (1). Its depletion might exacerbate chronic heart failure (CHF) (2,3).
It has been demonstrated that total cholesterol (TC) is related to survival in CHF (4–7). Rauchhaus et al. (5) reported that lower serum TC was independently associated with total mortality in a CHF cohort independent of etiology, age, left ventricular ejection fraction, and exercise capacity. The mechanisms postulated were that cholesterol might limit lipopolysaccharide-induced production of cytokines, and thus high levels of cholesterol might confer a survival advantage (5). They also postulated that high cholesterol might provide "greater metabolic reserve" to deal with the CHF syndrome. The authors did not, however, refer to CoQ10, which is known to correlate with TC concentration (8) and which might contribute to the worse outcomes seen in CHF patients with low cholesterol. Myocardial deficiency of CoQ10 has been demonstrated in heart failure, and the severity of the deficiency correlated with severity of symptoms. Patients in New York Heart Association (NYHA) functional class IV have significantly lower CoQ10 in endomyocardial biopsy samples than those in NYHA functional class I (3).
Although beneficial effects of CoQ10 supplementation in CHF have been reported (9–23) and intervention studies such as Q-SYMBIO have been initiated (24), CoQ10 levels have not been previously related to outcomes of heart failure in observational studies. Therefore, we tested the hypothesis that CoQ10 is associated with cholesterol and predicts mortality in patients with CHF.
|
Methods
|
|---|
This study was part of an ongoing cohort study of biomarkers in heart failure, with data collected systematically and prospectively. The CoQ10 hypothesis was generated retrospectively.
Patients.
Patients able to give informed consent were recruited during admission to Christchurch Hospital with symptomatic CHF satisfying Framingham (25) (2 major and 2 minor criteria present concurrently) and European Society of Cardiology (26) criteria, between July 2000 and December 2004. Plasma N-terminal peptide of B-type natriuretic peptide (NT-proBNP) was required to be over 50 pmol/l. Exclusion criteria included active myocarditis/pericarditis, life expectancy due to noncardiovascular disease of <24 months, severe hepatic or pulmonary disease (forced expiratory volume <1 l), renal impairment (plasma creatinine >250 µmol/l), transient heart failure from myocardial infarction (MI) treated with acute revascularization and a subsequent ejection fraction during the index hospital admission of >40%, severe valvular disease being considered for surgery, severe aortic stenosis (valve area <1 cm2), heart failure secondary to mitral stenosis, under consideration for cardiac transplantation, and age <18 years. A total of 3,576 patients were screened, yielding 998 eligible patients, of which 236 qualifying patients were enrolled. Eighty-four patients were excluded from the consented population on the basis of the exclusion criteria, primarily due to a reduction in NT-proBNP between consent (during hospital stay) and blood sampling. Qualifying patients visited within 28 days of the index hospital admission for collection of blood plasma samples, which were stored at –80°C.
At admission, all patients were severely symptomatic with heart failure. However, at the time of blood collection (median of 48 days after the index hospital admission), 65% were in NYHA functional class II. The median ejection fraction was 37%.
This study received ethical approval from the Canterbury Ethics Committee, and written informed consent was obtained from all participants.
Follow-up.
Patients were followed-up for a median of 2.69 (range 0.12 to 5.75) years. Patients were followed up at a minimum of 3 monthly intervals to document medications, adverse events, readmissions to hospital, and death. No patients were lost to follow-up. The primary end point of this study was all-cause mortality.
Measurement of analytes.
Plasma total CoQ10 was measured with high-performance liquid chromatography with electrochemical detection, similarly to Tang et al. (2001) (27). The within- and between-run coefficients of variation for the CoQ10 assay are approximately 3.3%. The TC was determined by an enzymatic colorimetric method (Aeroset analyser Model LN, Abbott Laboratories, Chicago, Illinois), with a coefficient of variation of 1.6%. Direct low-density lipoprotein cholesterol (LDL-C) was measured with Roche Diagnostics reagents (Indianapolis, Indiana), with a coefficient of variation of 1.2%. The NT-proBNP was measured by immunoassay, with a coefficient of variation of 13% (28). Glomerular filtration rate (GFR) was estimated by the modification of diet in renal disease (MDRD) study equation (29).
Statistical analysis.
Statistics were computed with SPSS version 11.5 (SPSS, Inc., Chicago, Illinois); p < 0.05 was considered significant. Due to skewed distributions, nonparametric statistics were used, and values are expressed as medians and ranges or percentages, as indicated. Reported correlations are Spearman rank correlations (R). To compare different predictive values at a particular time point, areas under the curve for sensitivity and specificity were constructed (receiver-operator characteristic [ROC] curve) (MedCalc 1993 to 2005, MedCalc Software, Mariakerke, Belgium). The best cutoff value for survival status at a given time point was defined as that point closest to the (0,1) point (the minimum Euclidean distance). Cox proportional hazards analyses were used to assess prognostic associations. A base model containing standard predictors of survival was constructed, which included age, gender, history of previous MI, glomerular filtration rate, and NT-proBNP, with additional factors added on to the base model as described. The hazard ratio (HR) with 95% confidence interval (CI) and p values by the likelihood ratio test are presented. Kaplan-Meier cumulative survival plots from date of admission were constructed with dichotomous data obtained with the cut-point from the ROC curve. Significance values for Kaplan-Meier curves are the log-rank comparisons. Differences in demographic variables for patients surviving more than and <1 year were compared with the Mann-Whitney rank sum test or chi-square test (Pearson chi-square 2-sided asymptotic significance).
|
Results
|
|---|
Samples from 236 patients were analyzed. The median (range) follow-up time was 2.7 (0.1 to 5.8) years. A total of 76 events (deaths) occurred. Maximum storage time for samples was 5.4 years. The patient demographic data of the complete cohort and the survivors and nonsurvivors at 1 year are shown in Table 1.
View this table:
[in this window]
[in a new window]
|
Table 1 Clinical and Biochemical Characteristics of All Patients at Index Hospital Admission and of Survivors and Nonsurvivors at 12 Months
|
|
There was a significant correlation between CoQ10 and TC (R = 0.663, p < 0.001) and LDL-C (R = 0.573, p < 0.001) and inversely between CoQ10 and NT-proBNP (R = –0.258, p < 0.001). There was also a weaker but significant negative correlation between TC and NT-proBNP (R = –0.190, p = 0.004).
The ROC curves were constructed for putative predictors of survival. Significant discrimination was observed for CoQ10 (Fig. 1), the ratios of CoQ10 to TC and CoQ10 to LDL-C, and also NT-proBNP and GFR (MDRD). A comparison of patient demographic data for patients with CoQ10 values higher and lower than the ROC curve optimal cut-point (0.73 µmol/l) (Fig. 1) is shown in Table 2. Neither TC nor LDL-C by themselves significantly differed from zero discrimination (diagonal on ROC curve), and hence no cutoff value for predicting survival could be determined. The ROC curve cut-points were also used in a multivariate analysis as outlined in the following text.
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Receiver-Operator Characteristic Curve for CoQ10
The receiver-operator characteristic curve for plasma coenzyme Q10 (CoQ10) (red line) as a predictor of total mortality, showing the optimal cut-point of 0.73 µmol/l. The green line represents the zero discrimination line.
|
|
View this table:
[in this window]
[in a new window]
|
Table 2 Clinical and Biochemical Characteristics of Patients With CoQ10 Concentrations Above and Below the Mortality ROC Curve Cut-Point (0.73 µmol/l)
|
|
Kaplan-Meier curves for CoQ10 (Fig. 2A), the CoQ10 to TC ratio, and the CoQ10 to LDL-C ratio—dichotomized for either the ROC curve cut-point or the median (data not shown)—showed significant differences in survival (p < 0.01), with lower CoQ10 and CoQ10 to lipid ratios predicting poorer survival. Additionally, a Kaplan-Meier curve for a 4-way split between CoQ10 and NT-proBNP showed significantly better survival related to high CoQ10 combined with low NT-proBNP levels compared with low CoQ10 and high NT-proBNP levels (Fig. 2B). There is significantly better survival associated with high CoQ10 plus high NT-proBNP than there is with low CoQ10 together with high NT-proBNP. And there is significantly better survival associated with low CoQ10 and low NT-proBNP than there is with low CoQ10 and high NT-proBNP (Fig. 2B).
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Survival Related to CoQ10 Concentration and to CoQ10 and NT-proBNP 4-Way Split
(A) Survival related to the best predictive value of mortality for coenzyme Q10 (CoQ10) as determined from the receiver-operator characteristic (ROC) curve (0.73 µmol/l), showing values above (green) and below (blue) this cut-point. Log-rank p < 0.001 for the difference between groups. (B) Kaplan-Meier survival curve for patients with above- and below-median CoQ10 in combination with above- and below-median N-terminal peptide of B-type natriuretic peptide (NT-proBNP). Differences in survival among patient groups are indicated, except where nonsignificant. Medians: CoQ10 = 0.68 µmol/l; NT-proBNP = 238 pmol/l. Values below graphs indicate the number of subjects remaining in the study at each time point.
|
|
Multivariable analysis allowing for effects of standard predictors of survival, including age at admission, gender, previous MI, estimated GFR (MDRD), and NT-proBNP, showed that CoQ10 was an independent predictor of survival, whether dichotomized at the ROC curve cut-point (HR: 1.99; 95% CI: 1.21 to 3.30, p = 0.007) or the median (0.68 µmol/l) (HR: 1.62; 95% CI: 1.01 to 2.59, p = 0.05) (Table 3). Total cholesterol was not a significant predictor of survival either added to the model as a continuous variable or dichotomized for the ROC curve cut-point of 5.2 mmol/l determined by Rauchhaus et al. (5) (Table 3).
The ratio of CoQ10 to TC was a significant predictor of survival when added to the base model as a continuous variable (HR [for a 10-U change in the CoQ10 to TC ratio]: 2.00; 95% CI: 1.03 to 3.85, p = 0.04) as well as when dichotomized for the median (median = 0.14 mmol/mol) (HR: 2.01; 95% CI: 1.23 to 3.31, p = 0.006). Similarly, the ratio of CoQ10 to LDL-C was close to significant predictor when added to the base model as a continuous variable (HR: 12.50; 95% CI: 0.97 to 100.00, p = 0.05) as well as dichotomized for the median (median = 0.26 mmol/mol) (HR: 1.61; 95% CI: 1.00 to 2.59, p = 0.05). Neither LDL-C nor TC dichotomized at the median or statins at discharge were independent predictors of survival when added to the base model, either independently or together.
|
Discussion
|
|---|
We have found an independent association between lower CoQ10 and increased risk of mortality in CHF. The strength of association between CoQ10 and mortality (HR: 1.99) was greater than that observed for NT-proBNP. The CoQ10 predicted outcome independently of NT-proBNP, suggesting that its longer-term contribution to function might be important regardless of the initial severity of the heart failure. The predictive power of CoQ10 was significant when included in the model dichotomized according to either the median value or ROC curve optimal cut-point for survival. It is recognized that CoQ10 deficiency occurs in CHF (3) and that this might compromise mitochondrial function. It is therefore plausible that CoQ10 deficiency might be an important pathogenic mechanism associated with worse outcomes in CHF. Follow-up samples to determine whether CoQ10 levels remain persistently depleted would provide interesting further information on the role of CoQ10 in heart failure.
We were unable to confirm an independent association of plasma cholesterol with total mortality, as has been previously reported (4–7). This might be due to differences in the 2 study populations. Rauchhaus et al. (5) enrolled patients with CHF from a CHF and cardiomyopathy clinic with duration of CHF between 6 months and 20 years. The majority were in NYHA functional class III (5). Our cohort was less symptomatic at the time of sampling and had various etiologies. Our group was older (median age 77 years in our study vs. mean ages of 63.0 and 62.1 years in the derivation and validation studies of Rauchhaus et al. [5], respectively) and was followed-up for a longer duration. Our patients were recruited during admission to the hospital with symptomatic CHF, with the majority being discharged in NYHA functional class II. These differences might account for the failure to confirm plasma cholesterol as a predictor of mortality.
It has also been shown that the myocardium in patients with heart failure is deficient in CoQ10 (3). Because plasma total CoQ10 concentrations correlate with TC, the ratio of CoQ10 to TC and/or LDL-C might be a better marker of CoQ10 status and hence survival. However, our results with the CoQ10 concentrations adjusted for lipids (TC or LDL-C) are similar to those with unadjusted CoQ10 concentrations, suggesting that the use of adjusted values offers no advantage.
The low number of events in our study (n = 76) is a limitation, and it is possible that some of the borderline associations found were affected by this. The low number of events also limited the number of baseline variables that could be added to the multivariable models, and, therefore, we have concentrated our analyses on the most established and accepted predictors of survival.
The association of CoQ10 and survival brings into question the role of statins in CHF. The role of statins in CHF is controversial (30); however, statin use has been associated with lower risk of death in patients with CHF (7,31). CoQ10 and cholesterol are both products of the mevalonate biosynthetic pathway, and statin therapy also lowers plasma total CoQ10 (32). If statins do confer benefit in CHF patients, it might be through mechanisms other than cholesterol reduction, so called pleiotropic effects. In 1 small study (33), CoQ10 reduction on statin therapy was associated with an improvement in endothelial function in CHF patients, suggesting that it might be a marker of pleiotropism. Larger and more long-term interventional studies with statins in CHF are required to assess the effect on clinical outcomes.
In our present study, patients with higher CoQ10 (above the ROC curve cut-point) were less likely to be receiving statins (or beta-blocker drugs); however, statin therapy at discharge from the index admission was not an independent predictor of survival, and CoQ10 remained an independent predictor of mortality in a multivariable model that included statin treatment. The CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) investigators failed to show a reduction in major vascular events in older patients with systolic heart failure (34). It could be postulated that this was due to a reduction in CoQ10 that offset any other beneficial effect of statin and warrants further investigation with a larger sample size than the current study.
Several clinical trials (10–17,19–22) have suggested benefits from CoQ10 supplementation in CHF. Two meta-analyses of CoQ10 supplementation in CHF have been conducted. Soja and Mortensen (9) used 8 double-blind placebo-controlled studies (10–17) and reported a significant improvement in stroke volume, ejection fraction, cardiac output, cardiac index, and end-diastolic volume index, as a consequence of CoQ10 supplementation. Changes in systolic time intervals and total work capacity were not statistically significant (9). More recently, Sander et al. (18) used 11 studies—10 that evaluated ejection fraction (10,12–14,17,19–22), and 2 that evaluated cardiac output (16,23)—with CoQ10 doses ranging from 60 to 200 mg/day and treatment periods ranging from 1 to 6 months. A 3.7% net improvement in the ejection fraction was found, and cardiac output was increased an average of 0.28 l/min (18). Recently an international multicenter intervention study, Q-SYMBIO, has been initiated (24). This is a randomized, double-blind, multicenter trial with focus on symptoms, biomarker status (B-type natriuretic peptide), and long-term outcomes (24).
No previous studies, however, have formally studied the relationship between CoQ10 and outcomes in CHF in a longitudinal observational study such as ours. Our findings in a clearly defined, prospectively studied group that CoQ10 depletion is associated with worse outcomes in CHF give further support to the rationale of the intervention studies that have already been initiated.
|
Conclusions
|
|---|
Plasma CoQ10 is an independent predictor of mortality in CHF. CoQ10 deficiency might be implicated in the long-term prognosis of CHF, and there is a rationale for further controlled intervention studies of CoQ10 supplementation.
|
Acknowledgments
|
|---|
The authors are grateful to the New Zealand Heart Foundation for grant support and thank members of the Cardioendocrine Research Group for management of the patient database and the heart failure patients for their participation.
|
Footnotes
|
|---|
This study and the salary for Dr. Molyneux were funded by the National Heart Foundation of New Zealand.
|
References
|
|---|
1. Crane FL, Hatefi Y, Lester RL, Widmer C. Isolation of a quinone from beef heart mitochondria Biochim Biophys Acta 1957;25:220-221.[Medline]2. Littarru GP, Ho L, Folkers K. Coenzyme Q10 in human heart disease. Part I and II. Int J Vitam Nutr Res 1972;42:291-305413–34.[Web of Science][Medline] 3. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10
Proc Natl Acad Sci U S A 1985;82:901-904.[Abstract/Free Full Text] 4. Horwich TB, Hamilton MA, MacLellan R, Fonarow GC. Low serum total cholesterol is associated with a marked increase in mortality in advanced heart failure J Am Coll Cardiol 2002;39:194A-195A. 5. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure J Am Coll Cardiol 2003;42:1933-1940.[Abstract/Free Full Text] 6. Vredevoe DL, Woo MA, Doering LV, Brecht ML, Hamilton MA, Fonarow GC. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy Am J Cardiol 1998;82:323-328.[CrossRef][Web of Science][Medline] 7. Anker SD, Clark AL, Winkler R, et al. Statin use and survival in patients with chronic heart failure—results from two observational studies with 5200 patients Int J Cardiol 2006;112:234-242.[CrossRef][Web of Science][Medline] 8. Molyneux SL, Florkowski CM, Lever M, George PM. Biological variation of coenzyme Q10
Clin Chem 2005;51:455-457.[Free Full Text] 9. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials Mol Aspects Med 1997;18:s159-s168.[CrossRef][Web of Science][Medline] 10. Judy WV, Hall JH, Toth PD, Folkers K. Double blind cross over study of coenzyme Q10 in heart failureIn: Folkers K, Yamamura Y, editors. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier; 1986. pp. 315-353. 11. Judy WV, Folkers K, Hall JH. Improved long-term survival in coenzyme Q10 treated chronic heart failure patients compared with conventionally treated patientsIn: Folkers K, Littarru GP, Yamagami T, editors. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier; 1991. 12. Morisco C, Nappi A, Argenziano L, et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment Mol Aspect Med 1994;15(Suppl):s155-s163.[CrossRef] 13. Permanetter B, Rössy W, Klein G, Weingartner F, Seidl KF, Blömer H. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy Eur Heart J 1992;13:1528-1533.[Abstract/Free Full Text] 14. Poggesi L, Galanti G, Comeglio M, Toncelli L, Vinci M. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. A medium-term randomised double-blind study versus placebo. Curr Ther Res 1991;49:878-886. 15. Schneeberger W, Müller-Steinwachs J, Anda LP, et al. A clinical double blind and crossover trial with coenzyme Q10 on patients with cardiac diseaseIn: Folkers K, Yamamura Y, editors. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier; 1986. pp. 325-333. 16. Serra G, Lissoni F, Piemonti C, Mazzola C. Evaluation of CoQ10 in patients with moderate heart failure and chronic stable effort anginaIn: Folkers K, Littarru GP, Yamagami T, editors. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier; 1991. pp. 327-338. 17. Hofman-Bang C, Rehnqvist N, Swedberg K, Wiklund I, Aström H. Coenzyme Q10 as an adjunctive in treatment of congestive heart failure J Card Fail 1995;1:101-107.[CrossRef][Medline] 18. Sander S, Coleman CI, Patel AA, Kluger J, White CM. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure J Card Fail 2006;12:464-472.[CrossRef][Web of Science][Medline] 19. Langsjoen P, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10
Proc Natl Acad Sci U S A 1985;82:4240-4244.[Abstract/Free Full Text] 20. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure J Am Coll Cardiol 1999;33:1549-1552.[Abstract/Free Full Text] 21. Keogh A, Fenton S, Leslie C, et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure Heart Lung Circ 2003;12:135-141.[CrossRef][Medline] 22. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure Ann Intern Med 2000;132:636-640.[Abstract/Free Full Text] 23. Munkholm H, Hansen HHT, Rasmussen K. Coenzyme Q10 treatment in serious heart failure Ann Intern Med 1999;9:285-289. 24. Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio"—a multinational trial. BioFactors 2003;18:79-89.[Web of Science][Medline] 25. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study J Am Coll Cardiol 1993;22:6A-13A.[Medline] 26. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology The treatment of heart failure Eur Heart J 1997;18:736-753.[Free Full Text] 27. Tang PH, Miles MV, DeGrauw A, Hershey A, Pesce A. HPLC analysis of reduced and oxidised coenzyme Q10 in human plasma Clin Chem 2001;47:256-265.[Abstract/Free Full Text] 28. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment Clin Endocrinol 1997;47:287-296.[CrossRef][Medline] 29. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Ann Intern Med 1999;130:461-470.[Abstract/Free Full Text] 30. Laufs U, Custodis F, Böhm M. HMG-CoA reductase inhibitors in chronic heart failure Drugs 2006;66:145-154.[CrossRef][Web of Science][Medline] 31. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure JAMA 2006;296:2105-2111.[Abstract/Free Full Text] 32. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans Proc Natl Acad Sci U S A 1990;87:8931-8934.[Abstract/Free Full Text] 33. Strey CH, Young JM, Molyneux SL, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure Atherosclerosis 2005;179:201-206.[CrossRef][Web of Science][Medline] 34. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure N Engl J Med 2007;357:2248-2261.[Abstract/Free Full Text]
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A31.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
V. Soukoulis, J. B. Dihu, M. Sole, S. D. Anker, J. Cleland, G. C. Fonarow, M. Metra, E. Pasini, T. Strzelczyk, H. Taegtmeyer, et al.
Micronutrient deficiencies an unmet need in heart failure.
J. Am. Coll. Cardiol.,
October 27, 2009;
54(18):
1660 - 1673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Methods